Skip to content
HowShorted

Tarsus Pharmaceuticals, Inc. short interest in 2021

In 2021, Tarsus Pharmaceuticals, Inc.'s disclosed short interest ran from 1.25% of shares outstanding on 15 Jan 2021 to 1.57% on 31 Dec 2021, a change of +0.32 percentage points. The year's high was 1.98% on 31 Mar 2021 and its low 1.25% on 15 Jan 2021, averaging 1.61% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 23.77 days on 30 Sep 2021. Full history: Tarsus Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Tarsus Pharmaceuticals, Inc. in 2021

2021 in figures

Start of year
1.25% (15 Jan 2021)
End of year
1.57% (31 Dec 2021)
Change
+0.32 pp
High
1.98% (31 Mar 2021)
Low
1.25% (15 Jan 2021)
Average
1.61%
Highest days to cover
23.77 (30 Sep 2021)
SEC filings marked
8

Every report in 2021

Tarsus Pharmaceuticals, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 20211.25%3.77
29 Jan 20211.28%8.82
12 Feb 20211.72%17.15
26 Feb 20211.82%8.37
15 Mar 20211.94%15.23
31 Mar 20211.98%12.3710-K filed, results (8-K)
15 Apr 20211.87%11.41
30 Apr 20211.87%10.10
14 May 20211.81%5.0310-Q filed, results (8-K)
28 May 20211.53%5.53
15 Jun 20211.37%5.21
30 Jun 20211.55%1.94
15 Jul 20211.60%12.15
30 Jul 20211.55%9.04
13 Aug 20211.51%9.2010-Q filed, results (8-K)
31 Aug 20211.48%11.07
15 Sep 20211.60%11.33
30 Sep 20211.60%23.77
15 Oct 20211.61%7.89
29 Oct 20211.57%12.33
15 Nov 20211.51%6.65results (8-K), 10-Q filed
30 Nov 20211.53%12.46
15 Dec 20211.57%15.95
31 Dec 20211.57%15.00

See also: Tarsus Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.